Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system-Reference-Cited by-同舟云学术

Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Published:2024-07-23 Issue: Volume: Page:1-13
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Zhao Ruiqi¹,Han Mengyao²,Lin Sen¹,Lin Zhimei¹,Yu Mengjiao¹,Zhang Bei¹,Ma Lanyue¹,Li Danfei¹,Peng Lisheng³^ORCID

Affiliation:

1. The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China

2. The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

3. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China

Funder

Science, Technology and Innovation Commission of Shenzhen Municipality

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2380513

Reference72 articles.

1. Cancer mortality in Europe, 1990–1994, and an overview of trends from 1955 to 1994

2. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4

3. Metabolic Signatures: Pioneering the Frontier of Rectal Cancer Diagnosis and Response to Neoadjuvant Treatment with Biomarkers—A Systematic Review

4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

5. National Center for Biotechnology Information. PubChem compound summary for CID 3385 Fluorouracil. [cited 2024 Mar 27]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Fluorouracil

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10